Antonio Michelucci

Antonio Michelucci

Auto-generated profile, based on publicly available information

Antonio Michelucci

University of Florence

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2004
Verified
Journal Article
Closed access
RSRoberto Sciagrà
Roberto Sciagrà
MGMarzia Giaccardi
Marzia Giaccardi
MPMaria Cristina Porciani
Maria Cristina Porciani
ACAndrea Colella
Andrea Colella
AMAntonio Michelucci
Antonio Michelucci
LPLuigi Padeletti
Luigi Padeletti

5 July 2004 in Annals of Noninvasive Electrocardiology
Verified
Journal Article
Open access
PDF file
FFFrancesco Furlanello
Francesco Furlanello
GGGiorgio GALANTI
Giorgio GALANTI
PMPaolo Manetti
Paolo Manetti
ACAndrea Capalbo
Andrea Capalbo
NPNicola Pucci
Nicola Pucci
CRCappato Riccardo
Cappato Riccardo
Background: Several studies have confirmed the equivalence of the microvolt T‐wave alternans (mTWA) and the electrophysiology (EPS) tests in cardiac disease. No data are available in populations of competitive athletes with arrhythmias that might jeopardize the pursuit of their professional career. Methods: We prospectively studied 100 trained competitive athletes, including elite types (72/100), (mean age ± standard deviation: 26.1 ± 4.5 years). Forty‐eight of them were wholly normal (Group A, mean age: 24.5 ± 8.5 years) and 52 of them had severe arrhythmias (Group B, mean age: 28.2 ± 11.5 years) and were symptomatic in 85% of cases for prolonged palpitations and syncope, but lacked any overt structural heart disease at standardized cardiological screening.All athletes were evaluated with the microvolt T‐wave alternans exercise–stress test, using the Heart Wave System with Microvolt Sensors. Group B underwent EPS to evaluate inducibility to sustained ventricular tachycardia (VT) during programmed electrical stimulation. Results: In Group A, the mTWA outcome was determinate in 45 subjects (94%) and indeterminate in 3 (6%). No symptomatic event was reported in a follow‐up of 36.1 months. In Group B, the mTWA test was positive in 7 symptomatic subjects (15%), indeterminate in 3 (7%), and negative for the remaining 42 subjects (76%). Forty‐one of 42 negative mTWA subjects were also negative in the EPS test, without any syncope or sustained VT during 25.3 months of follow‐up. In the positive mTWA test subjects, 5 (72%) were positive for inducibility of rapid sustained monomorphic VT in EPS, 1 was positive for severe sustained atrial tachyarrhythmias, and 1 refused EPS. We were able to pronounce a correct diagnosis of lymphocytic myocarditis for only 1 mTWA and EPS‐positive subject. For the other 4 positive patients with arrhythmogenic micropathology, severe arrhythmic events were revealed in the follow‐up and aggressive hybrid treatment was necessary. Conclusion: Microvolt‐TWA study seems to be a useful, noninvasive, and feasible tool for evaluating arrhythmic risk in the athletic population. The mTWA test showed a high negative predictive value, using both EPS and the follow‐up observation for severe arrhythmic cardiac events as an endpoint. The positive predictive value was present in a limited number of cases that were, however, subjects with a high risk of sudden arrhythmic death.

15 October 2020 in Journal of Cardiothoracic Surgery
Verified
Journal Article
Open access
PDF file
PSPier Luigi Stefàno
Pier Luigi Stefàno
MBMarco Bugetti
Marco Bugetti
GMGuido Del Monaco
Guido Del Monaco
GPGloria Popescu
Gloria Popescu
PPPaolo Pieragnoli
Paolo Pieragnoli
AMAntonio Michelucci
Antonio Michelucci
Background: Body mass index (BMI), age, left atrium (LA) dimension and left ventricular ejection fraction (LVEF) have been linked to post-operative atrial fibrillation (POAF) after cardiac surgery. The aim of this study was to better define the role of these risk factors. Methods: This retrospective cohort study evaluated 249 patients (without prior atrial dysrhythmia) undergoing cardiac or aortic surgery. Prior to surgery, the following data were collected: age, BMI, LA diameter, LA area, LVEF, thyroid stimulating hormone (TSH), creatinine and the presence of arterial hypertension (AH) and diabetes. Intraoperative data such as operation time, total clamp time, cardiopulmonary bypass time, and presence of pericardial/pleural effusion were also collected. Only patients without pre- and post-surgery prophylactic anti-arrhythmic therapy were included. Results: Patients with (N = 127, 51%) and without POAF (N = 122, 49%) were compared. No difference was observed for sex, LA diameter, LA area, LVEF, TSH, diabetes and use of ACE inhibitors or statins prior to intervention. Moreover, no difference was observed in terms of operation time, total clamp time, cardiopulmonary bypass time, and presence of pericardial/pleural effusion. However, patients with POAF were older (70.6 ± 10.7 vs. 60.4 ± 16.4 years, p = 0.001), had higher BMI (26.8 ± 4.5 vs. 24.9 ± 3.6 kg/m2, p = 0.001), higher baseline creatinine (1.06 ± 0.91 vs. 0.88 ± 0.32 mg/dL, p = 0.038) and a higher frequency of arterial hypertension (73.2% vs. 50%, p = 0.001) and Bentall procedure (24.4% vs. 9.8%, p = 0.023). Multivariate analysis showed that the only independent predictors of POAF were age (OR = 1.05, 95%CI 1.02–1.07, p = 0.001) and BMI (OR = 1.11 95%CI 1.03–1.2,p = 0.006). Conclusions: These findings suggest that advanced age and a higher BMI are strong risk factors for POAF in patients without previous AF even in the presence of comparable LA dimensions and LVEF.

6 November 2011 in Pacing and Clinical Electrophysiology
Verified
Journal Article
Closed access
PDF file
LPLaura Perrotta
Laura Perrotta
GRGiuseppe Ricciardi
Giuseppe Ricciardi
PPPaolo Pieragnoli
Paolo Pieragnoli
MCMarco Chiostri
Marco Chiostri
GPGiulia Pontecorboli
Giulia Pontecorboli
LPLuigi Padeletti
Luigi Padeletti

1 September 2004 in EP Europace
Verified
Journal Article
Closed access
LPL Padeletti
L Padeletti
NMN Musilli
N Musilli
MPM Porciani
M Porciani
ACA Colella
A Colella
LDL Dibiase
L Dibiase
GGG Gensini
G Gensini
Atrial fibrillation (AF) and congestive heart failure (CHF) share several characteristics and often coexist in the same patient. Both are responsible for significant morbidity and mortality, are increasing in prevalence, and are major sources of health expenditure. The Management of Atrial fibrillation Suppression in AF-HF COmorbidity Therapy (MASCOT) study is a European, single-blind, prospective, controlled, multicentre, randomized clinical trial designed to examine whether adding the AF Suppression Algorithm to cardiac resynchronization therapy (CRT) improves the prognosis of patients with CHF. The patients will be randomly assigned to a CRT-only group, with the AF Suppression algorithm programmed OFF (control group), versus a CRT+AF Suppression group, with the algorithm programmed ON (treatment group). The primary study endpoint is development of permanent AF, and secondary endpoints are safety of the AF Suppression algorithm, and evolution of multiple clinical variables over 24 months of follow-up. CRT combined with a refined atrial tachyarrhythmia prevention pacing algorithm may represent a major advance in the management of AF and CHF by electrical stimulation.

1 January 2009
Verified
Journal Article
Closed access
RTRoberto Tarquini
Roberto Tarquini
CGCristina Tosti Guerra
Cristina Tosti Guerra
MPMaria Cristina Porciani
Maria Cristina Porciani
AMAntonio Michelucci
Antonio Michelucci
MPMargherita Padeletti
Margherita Padeletti
LPLuigi Padeletti
Luigi Padeletti